A pilot study comparing corifollitropin alfa associated with hp-HMG versus high dose rFSH antagonist protocols for ovarian stimulation in poor responders

References

• Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology. (2017). Human Reproduction, 32, i1–i539. doi: 10.1093/humrep/32.Supplement_1.1.
   PubMed Web of Science ®Google Scholar
• Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. (2011). The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Human Reproduction, 26, 1270–1283. doi: 10.1093/humrep/der037.
   PubMed Web of Science ®Google Scholar
• Baart, E.B., Martini, E., Eijkemans, M.J., Van Opstal, D., Beckers, N.G.M., Verhoeff, A., … Fauser, B.C.J.M. (2007). Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: A randomized controlled trial. Human Reproduction, 22, 980–988. doi: 10.1093/humrep/del484.
   PubMed Web of Science ®Google Scholar
• Baker, V.L., Brown, M.B., Luke, B., Smith, G.W., & Ireland, J.J. (2015). Gonadotropin dose is negatively correlated with live birth rate: Analysis of more than 650,000 assisted reproductive technology cycles. Fertility and Sterility, 104, 1145–1152. doi: 10.1016/j.fertnstert.2015.07.1151.
   PubMed Web of Science ®Google Scholar
• Bosch, E., Labarta, E., Crespo, J., Simón, C., Remohí, J., & Pellicer, A. (2011). Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertility and Sterility, 95, 1031–1036. doi: 10.1016/j.fertnstert.2010.10.021.
   PubMed Web of Science ®Google Scholar
• Bosch, E., Labarta, E., Kolibianakis, E., Rosen, M., & Meldrum, D. (2016). Regimen of ovarian stimulation affects oocyte and therefore embryo quality. Fertility and Sterility, 105, 560–570. doi: 10.1016/j.fertnstert.2016.01.022.
   PubMed Web of Science ®Google Scholar
• Bozdag, G., Polat, M., Yarali, I., & Yarali, H. (2017). Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria. Reproductive Biomedicine Online, 34, 639–644. doi: 10.1016/j.rbmo.2017.03.009.
   PubMed Web of Science ®Google Scholar
• Busnelli, A., Papaleo, E., Del Prato, D., La Vecchia, I., Iachini, E., Paffoni, A., … Somigliana, E. (2015). A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Human Reproduction, 30, 315–322. doi: 10.1093/humrep/deu319.
   PubMed Web of Science ®Google Scholar
• Busnelli, A., & Somigliana, E. (2018). Prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Minerva Ginecologica, 70, 89–98. doi: 10.23736/S0026-4784.17.04132-6.
   PubMed Web of Science ®Google Scholar
• Dahan, M.H., Agdi, M., Shehata, F., Son, W., & Tan, S.L. (2014). A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 172, 70–73. doi: 10.1016/j.ejogrb.2013.10.027.
   PubMed Web of Science ®Google Scholar
• Dercourt, M., Barriere, P., & Freour, T. (2016). Stimulation ovarienne à fortes doses de gonadotrophines en FIV: étude rétrospective cas-témoin au CHU de Nantes [High doses of gonadotropins for controlled ovarian hyperstimulation: a case-control study]. Gynecologie, Obstetrique & Fertilite, 44, 29–34. doi: 10.1016/j.gyobfe.2015.09.014.
   PubMedGoogle Scholar
• Devine, K., Mumford, S.L., Wu, M., DeCherney, A.H., Hill, M.J., & Propst, A. (2015). Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the society for assisted reproductive technology clinic outcomes reporting system. Fertility and Sterility, 104, 612–619.e3. doi: 10.1016/j.fertnstert.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Devroey, P., Boostanfar, R., Koper, N.P., Mannaerts, B.M.J.L., IJzerman-Boon, P.C., & Fauser, B.C.J.M. (2009). A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction, 24, 3063–3072. doi: 10.1093/humrep/dep291.
   PubMed Web of Science ®Google Scholar
• Doan, H.T., Quan, L.H., & Nguyen, T.T. (2017). The effectiveness of transdermal testosterone gel 1% (androgel) for poor responders undergoing in vitro fertilization. Gynecological Endocrinology, 33, 977–979. doi: 10.1080/09513590.2017.1332586.
   PubMed Web of Science ®Google Scholar
• Drakopoulos, P., Vuong, T.N.L., Ho, N.A.V., Vaiarelli, A., Ho, M.T., Blockeel, C., …., Polyzos, N.P. (2017). Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: A multicentre randomized controlled clinical trial. Human Reproduction, 32, 2225–2233. doi: 10.1093/humrep/dex296.
   Google Scholar
• Fauser, B.C.J.M., Mannaerts, B.M.J.L., Devroey, P., Leader, A., Boime, I., & Baird, D.T. (2009). Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Human Reproduction Update, 15, 309–321. doi: 10.1093/humupd/dmn065.
   PubMed Web of Science ®Google Scholar
• Ferraretti, A.P., La Marca, A., Fauser, B.C.J.M., Tarlatzis, B., Nargund, G., Gianaroli, L. & Eshre Working Group On Poor Ovarian Response Definition. (2011). ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitro fertilization: The Bologna criteria. Human Reproduction, 26, 1616–1624. doi: 10.1093/humrep/der092.
   PubMed Web of Science ®Google Scholar
• Griesinger, G., Boostanfar, R., Gordon, K., Gates, D., McCrary Sisk, C., & Stegmann, B.J. (2016). Corifollitropin alfa versus recombinant follicle-stimulating hormone: An individual patient data meta-analysis. Reproductive Biomedicine Online, 33, 56–60. doi: 10.1016/j.rbmo.2016.04.005.
   PubMed Web of Science ®Google Scholar
• Griesinger, G., Verweij, P.J.M., Gates, D., Devroey, P., Gordon, K., Stegmann, B.J., & Tarlatzis, B.C. (2016). Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol. PLoS One, 11, e0149615. doi: 10.1371/journal.pone.0149615.
   PubMed Web of Science ®Google Scholar
• Haas, J., Zilberberg, E., Kedem, A., Dar, S., & Orvieto, R. (2015). Do poor-responder patients benefit from increasing the daily gonadotropin dose from 300 to 450 IU during controlled ovarian hyperstimulation for IVF? Harefuah, 154, 114–117, 135.
   PubMedGoogle Scholar
• Humaidan, P., Chin, W., Rogoff, D., D'Hooghe, T., Longobardi, S., Hubbard, J., & Schertz, J. (2017). Efficacy and safety of follitropin alfa/lutropin alfa in ART: A randomized controlled trial in poor ovarian responders. Human Reproduction, 32, 1537–1538. doi: 10.1093/humrep/dex208.
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Alviggi, C., Fischer, R., & Esteves, S.C. (2016). The novel POSEIDON stratification of ‘low prognosis patients in assisted reproductive technology’ and its proposed marker of successful outcome. F1000Research, 5, 2911. doi: 10.12688/f1000research.10382.1.
   PubMedGoogle Scholar
• Kolibianakis, E.M., Venetis, C.A., Bosdou, J.K., Zepiridis, L., Chatzimeletiou, K., Makedos, A., … Tarlatzis, B.C. (2015). Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: A randomized controlled trial. Human Reproduction, 30, 432–440. doi: 10.1093/humrep/deu301.
   PubMed Web of Science ®Google Scholar
• König, T.E., van der Houwen, L.E.E., Overbeek, A., Hendriks, M.L., Beutler-Beemsterboer, S.N., Kuchenbecker, W.K.H., … Lambalk, C.B. (2013). Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction, 28, 2804–2812. doi: 10.1093/humrep/det266.
   PubMed Web of Science ®Google Scholar
• Lainas, T.G., Sfontouris, I.A., Venetis, C.A., Lainas, G.T., Zorzovilis, I.Z., Tarlatzis, B.C., & Kolibianakis, E.M. (2015). Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders. Human Reproduction, 30, 2321–2330. doi: 10.1093/humrep/dev198.
   PubMed Web of Science ®Google Scholar
• Lerman, T., Depenbusch, M., Schultze-Mosgau, A., von Otte, S., Scheinhardt, M., Koenig, I., … Griesinger, G. (2017). Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study. Reproductive Biomedicine Online, 34, 534–540. doi: 10.1016/j.rbmo.2017.02.012.
   PubMed Web of Science ®Google Scholar
• Mochtar, M.H., Danhof, N.A., Ayeleke, R.O., V. D., Veen, F., V., & Wely, M. (2017). Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. The Cochrane Database of Systematic Reviews, 5, CD005070. doi: 10.1002/14651858.CD005070.pub3.
   PubMed Web of Science ®Google Scholar
• Nagels, H.E., Rishworth, J.R., Siristatidis, C.S., & Kroon, B. (2015). Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. The Cochrane Database of Systematic Reviews, 11, CD009749. doi: 10.1002/14651858.CD009749.pub2.
   PubMed Web of Science ®Google Scholar
• Papathanasiou, A., Searle, B.J., King, N.M.A., & Bhattacharya, S. (2016). Trends in ‘poor responder’ research: lessons learned from RCTs in assisted conception. Human Reproduction Update, 22, 306–319. doi: 10.1093/humupd/dmw001.
   PubMed Web of Science ®Google Scholar
• Polyzos, N.P., De Vos, M., Corona, R., Vloeberghs, V., Ortega-Hrepich, C., Stoop, D., & Tournaye, H. (2013). Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: A pilot study. Human Reproduction, 28, 1254–1260. doi: 10.1093/humrep/det045.
   PubMed Web of Science ®Google Scholar
• Polyzos, N.P., Camus, M., Llacer, J., Pantos, K., & Tournaye, H. (2013). Corifollitropin α followed by menotropin for poor ovarian responders’ trial (COMPORT): A protocol of a multicentre randomised trial. BMJ Open, 3, e002938. doi: 10.1136/bmjopen-2013-002938.
   PubMed Web of Science ®Google Scholar
• Polyzos, N.P., Corona, R., Van De Vijver, A., Blockeel, C., Drakopoulos, P., Vloeberghs, V., … Tournaye, H. (2015). Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders. Gynecological Endocrinology, 31, 885–890. doi: 10.3109/09513590.2015.1065481.
   PubMed Web of Science ®Google Scholar
• Polyzos, N.P., DeVos, M., Humaidan, P., Stoop, D., Ortega-Hrepich, C., Devroey, P., & Tournaye, H. (2013). Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertility and Sterility, 99, 422–426. doi: 10.1016/j.fertnstert.2012.09.043.
   PubMed Web of Science ®Google Scholar
• Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number); Alviggi, C., Andersen, C.Y., Buehler, K., Conforti, A., De Placido, G., Esteves, S.C., … Humaidan, P. (2016). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertility and Sterility, 105, 1452–1453. doi: 10.1016/j.fertnstert.2016.02.005.
   Google Scholar
• Pouwer, A.W., Farquhar, C., Kremer, J.A.M., & Marjoribanks, J. (2016). Long-acting follicle-stimulating hormone versus daily follicle-stimulating hormone for women undergoing assisted reproduction. Fertility and Sterility, 105, 1454–1456. doi: 10.1016/j.fertnstert.2016.01.041.
   PubMed Web of Science ®Google Scholar
• Salgueiro, L.L., Rolim, J.R., Moura, B.R.L., Machado, S.P.P., & Haddad, C. (2016). Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol. JBRA Assisted Reproduction, 20, 123–126. doi: 10.5935/1518-0557.20160028.
   PubMed Web of Science ®Google Scholar
• Sekhon, L., Shaia, K., Santistevan, A., Cohn, K.H., Lee, J.A., Beim, P.Y., & Copperman, A.B. (2017). The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response. Journal of Assisted Reproduction and Genetics, 34, 749–758. doi: 10.1007/s10815-017-0909-3.
   PubMed Web of Science ®Google Scholar
• Siristatidis, C., Salamalekis, G., Dafopoulos, K., Basios, G., Vogiatzi, P., & Papantoniou, N. (2017). Mild versus conventional ovarian stimulation for poor responders undergoing IVF/ICSI. In Vivo, 31, 231–237. doi: 10.21873/invivo.11050.
   PubMed Web of Science ®Google Scholar
• Souza, P.M.G., de Carvalho, B.R., Nakagawa, H.M., Rassi, T.R.E., Barbosa, A.C.P., & Silva, A.A. (2017). Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction. JBRA Assisted Reproduction, 21, 67–69. doi: 10.5935/1518-0557.20170017.
   PubMed Web of Science ®Google Scholar
• Vuong, T.N.L., Phung, H.T., & Ho, M.T. (2015). Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction, 30, 1188–1195. doi: 10.1093/humrep/dev038.
   PubMed Web of Science ®Google Scholar
• Younis, J.S., Izhaki, I., & Ben-Ami, M. (2014). The effect of LH supplementation following GnRH antagonist administration in advanced reproductive ageing women undergoing IVT-ET: a prospective randomized controlled study. Fertility and Sterility, 102, e23. doi: 10.1016/j.fertnstert.2014.07.085.
   Web of Science ®Google Scholar